Prevention of infections is of obvious relevance in paediatric patients with acute myeloid leukaemia (AML). However, recommendations are often non-specific and supported by low-quality evidence, resulting in divergent infection preventive regimens. Using a web-based survey, we investigated the infection prophylaxis guidelines of 22 paediatric AML study groups affiliated to the international Berlin-Frankf€ urt-M€ unster study group. In order to evaluate differences in daily practice among hospitals, representatives (n = 27) from the Nordic Society for Paediatric Haematology and Oncology-Dutch-Belgium-Hong Kong -AML study group participated in a slightly modified survey. Seven study groups (32%) advise gram-negative antibiotic prophylaxis, mainly with fluoroquinolones (n = 6). Gram-positive prophylaxis is prescribed by eight groups (36%). Over 60% of the study groups prescribe food and social restrictions, but the specific topics and strictness differ widely. According to the hospital-based survey, sites roughly comply with common study group guidelines. However, the use of any gram-negative antibiotic prophylaxis, the specific prophylactic antifungal agent and the strictness of the food and social restrictions differ substantially between the hospitals. Despite a long history of close collaboration, many differences are still present between the affiliated groups. The results of this survey provide an appropriate baseline measure to study the emergence and impact of future guidelines on infection prophylaxis in paediatric AML.
Although the long-term overall survival of paediatric acute myeloid leukaemia (AML) patients has improved substantially over the past decades, intensification of treatment protocols and high doses of chemotherapy have led to an increase of treatment-related complications, with severe infections being one of the most important risks. Not only does intensive chemotherapy cause profound and prolonged neutropenia, disruption of skin and mucosal barriers, hospitalization, multiple invasive procedures and the required use of a central venous line (CVL) all increase the risk of infection. Up to 80% of paediatric AML patients suffer from at least one bacterial (blood stream) infection during treatment, with an average of 2Á8 infectious complications per patient. Aside from fungal infections, bacterial infections with gram-negative species and gram-positive Viridans Group Streptococci (VGS) are notorious for their frequent complications and poor outcome (Sung et al, 2007; Lehrnbecher & Sung, 2014) . In order to lower the incidence of infections, many anti-infective measures have been suggested, such as prophylactic antibiotics and antifungal agents, granulocyte colony-stimulating factor (G-CSF) and food-or social restrictions. In the past, several studies have tried to provide solid evidence for the best supportive care measures, but very few have generated clear conclusions or strong recommendations. Available studies are often limited by retrospective designs and/or small patients numbers and currently available guidelines mainly target a more general population of children with cancer, without acknowledging disease specific risks or complications (Lehrnbecher et al, 2012a; Loeffen et al, 2017) .
Pharmacological prophylaxis is generally recommended for adult patients with AML (Gafter-Gvili et al, 2012) , but the role of prophylactic medicines in paediatric AML remains uncertain (Lehrnbecher & Sung, 2014) . Despite appeals by experts and working groups in the field to harmonize guidelines, many divergent regimens exist among hospitals and study groups (Lehrnbecher et al, 2009 (Lehrnbecher et al, , 2012b Loeffen et al, 2016a) . Whereas previous surveys on this matter mainly focused on hospital-based recommendations, the aim of the current study was to gain insight in all available infection prophylaxis guidelines for paediatric AML patients within the international Berlin-Frankf€ urt-M€ unster Study Group (I-BFM-SG).
Materials and methods
The I-BFM-SG comprises a large international paediatric AML consortium, in which most developed (Western) countries are represented. In order to gain insight in the current guidelines among the different paediatric AML study groups, the chairs of the I-BFM-SG, the Nordic Society for Paediatric Hematology and Oncology (NOPHO) group, the Dutch Childhood Oncology Group (DCOG), and the Belgian Society of Paediatric Haematology Oncology (BSPHO) developed a web-based questionnaire. After a literature study with evaluation of previous surveys on the topic, items were selected for inclusion in the questionnaire upon expert decision by these chairs and the coordinating researcher. The survey (Data S1) included questions on the use of pharmacological prophylactic measures, e.g. antibiotics, antifungal medication, antiviral prophylaxis, G-CSF, non-pharmacological in-hospital measures, e.g. the use of isolation rooms, and out-patient recommendations, e.g. food or social restrictions, and outpatient clinic visits. In order to check for discordant answers or inconsistencies, a copy of the formal study group guidelines (if available) was requested.
Prior to dissemination, the questionnaire was pilot-tested among 9 paediatric oncologists and paediatric oncologists in training and 2 paediatric oncology nurse practitioners. Small adjustments were made based on their comments. Through the chair of the I-BFM-SG, up-to-date contact information of the representatives of all affiliated international study groups was collected, after which the link to the online questionnaire was disseminated by email. All non-responding representatives received up to four reminders, including three per email and one during an international meeting.
To gain more insight in the daily practice arising from the study group guidelines, we also investigated the recommendations and use of infection prophylactic measures on a hospital-based level. All hospitals affiliated to the NOPHODutch-Belgium-Hong Kong (DBH) AML study group, including the NOPHO, DCOG, BSPHO and Hong Kong were invited to complete a slightly modified version of the I-BFM-SG questionnaire (Data S2). The representatives of the three main regions of the NOPHO-DBH AML study group, i.e. Scandinavia, the Netherlands and Belgium, disseminated the other survey among the hospital representatives. These representatives received up to two reminders by email and one personal reminder during a regular meeting.
Statistical analyses
Due to the explorative nature of this study, mainly descriptive data (numbers and percentages) of the surveys are presented.
Results
Of the 26 study groups that were contacted, 22 (85%) ultimately responded (Data S3). One study group responded by e-mail but did not complete the questionnaire because they had no general guidelines within their study group/country. The representative of this group reported back to us that all anti-infective supportive care measures were left up to the individual centres. Another study group responded by providing their guidelines but without completing the questionnaire.
Pharmacological infection prophylaxis
The guidelines of almost all study groups recommend Pneumocystis jiroveci pneumonia (PJP) prophylaxis with trimethoprim-sulfamethoxazole (n = 21, 95%). Gram-negative prophylaxis was included in seven of the guidelines (32%) and mainly involved fluoroquinolones (n = 6). One study group advises Paromomycin decontamination. The majority of study groups (n = 12, 55%) do not recommend grampositive or VGS prophylaxis on a regular basis. Six guidelines include prophylaxis with either penicillin-like derivatives, vancomycin or teicoplanin. Two groups recommend prophylaxis only in specific cases, such as following courses with high-dose cytarabine (HD-AraC). All but one study groups advise antifungal prophylaxis. Half of the study groups leave the choice of agent up to the hospitals. Table I shows the details on the distribution and recommendations of pharmacological infection prophylactic measures.
In cases of febrile neutropenia, the study groups mainly prescribe cephalosporins or piperacillin/tazobactam with or without aminoglycosides or glycopeptides. None of the study groups specifically mentioned the use of (additional) empirical antibiotics with gram-positive coverage after HD-AraC. In cases of suspected fungal infection, mainly liposomal amphotericin B (L-AmB) is recommended. Figure S1 shows the distributions and agents used as empirical therapy in suspected bacterial or fungal infections.
One study group prescribes antiviral prophylaxis for children <2 years of age on a regular basis, the other study groups have no recommendations on this matter or prescribe it only in specific cases, e.g. recurrent Herpes Simplex Virus and exposure to Varicella Zoster Virus in seronegative patients. Most of the study groups do not recommend the use of G-CSF at all (n = 10, 46%), or only in specific cases of severe infections and/or prolonged neutropenia (n = 7, 32%).
Food and social restrictions
Most frequently reported food restrictions involve consumption of raw meat and raw seafood (n = 16, 76%), unpasteurized milk products (n = 14, 67%), dishes with undercooked eggs (n = 13, 62%), shellfish (n = 11, 52%), pre-/probiotics (n = 11, 52%) and soft ice cream (n = 11, 52%). One study group does not define any specific restrictions and one study group does not restrict any food. Four study groups do not have recommendations with regard to food restrictions and leave the decision up to the treating physicians.
Eight study groups (36%) have no recommendations with regard to social restrictions. All other study groups reported social restrictions. Frequently reported social restrictions include visiting indoor crowded places (n = 13, 62%), using public transportation (n = 12, 57%), visiting day-care/kindergarten/pre-school (n = 12, 57%) and visiting subtropical swimming pools (n = 12, 57%). Ten study groups (48%) restrict going to school. Study groups who recommend antibiotic prophylaxis were similarly stringent with regard to social or food restrictions and outpatient management compared with study groups who do not recommend antibiotic prophylaxis. Table II shows the distribution and recommendation of non-pharmacological infection prophylactic measures. Tables SI and SII show details and distributions of all items with regard to food and social restrictions, respectively.
Hospital-based survey
Within the NOPHO-DBH AML study group, 27 of the 30 (90%) contacted hospital representatives filled out the questionnaire. One hospital responded that they no longer treat de novo AML patients. Data S3 shows the participating hospitals within the NOPHO-DBH AML Study Group. Table III shows the most important results of the hospital-based survey.
Differences between study group guidelines and hospitalbased practice
The pharmacological recommendations of most centres were similar to the guidelines of their study group (i.e. NOPHO, DCOG, BSPHO). Hong Kong and NOPHO-affiliated hospitals seldom prescribe gram-negative antibiotic prophylaxis, whereas most BSPHO and all DCOG-affiliated hospitals prescribe prophylaxis with fluoroquinolones. The use of Grampositive prophylaxis was more ambiguous among the three study groups, as was the use of specific agents, especially 
Discussion
Despite a long history of close collaboration within the AML I-BFM-SG, this study shows that many differences with regard to infection preventive measures are still present between the affiliated paediatric AML study groups. Our results are in line with a previous report on differences between hospital recommendations within the German AML-BFM study group and the Children's Oncology Group (COG) (Lehrnbecher et al, 2009) . That study focused on hospital-based differences, whereas we focused on study group guidelines. Secondarily, we studied a limited number of affiliated hospitals from the NOPHO-DBH consortium. We were not able to include all hospitals from all study groups, but it seems reasonable to believe that the observed differences between hospitals from both the previous study and ours can be extrapolated to hospital-based differences within other international study groups. Although evidence to support the recommendations on the use of PJP prophylaxis in AML patients is relatively poor (Stern et al, 2014) , sulfonamides are prescribed by virtually all of the study groups and hospitals. Another important finding of the study group survey was the discordance in prophylactic antibiotic use. Numerous studies have focused on the question of whether the benefits of antibiotic prophylaxis in paediatric patients with haematological malignancies outweigh the disadvantages, but large prospective Information available for 21 of the 22 participating study groups. Percentages were calculated without 'unknown'. Percentages may not total 100% due to rounding. ANC, absolute neutrophil count. *Specific food and social food restrictions are specified in Table SI and SII, respectively. †The most important food restrictions included raw meat/fish (counted as 1 restriction), raw shellfish, unpasteurized milk products, dishes with undercooked eggs. ‡The most important social restrictions included day-care/pre-school, subtropical swimming pools, public transportation, indoor crowded places. §Patients stay at the hospital between courses or are only "on leave" awaiting their next course for a (very) few days if they are in good clinical condition. randomized trials are lacking. Based on a meta-analysis and a Cochrane review, antibiotic prophylaxis, especially with (fluoro)quinolones, is considered to reduce the number of infections and decrease overall mortality in adults (Gafter-Gvili et al, 2012) . Fluoroquinolone prophylaxis is recommended by the American Society of Infectious Diseases for high-risk patients, such as AML patients (Freifeld et al, 2011) . However, in paediatric AML the debate is still on-going (Alexander et al, 2012) and is reflected in our results. If antibacterial prophylaxis is advocated, the study groups usually recommend the use of quinolones. This policy is supported by a small number of paediatric studies, but is mainly based on recommendation in adults (Yousef et al, 2004; Gafter-Gvili et al, 2005; Sung et al, 2013; Yeh et al, 2014; Felsenstein et al, 2015) . Its use is under dispute because of conflicting findings on efficacy, the potential risk of resistance and the association with an increase in fungal infections (Felsenstein et al, 2015) . Specific VGS prophylaxis with penicillin or vancomycin is recommended by a minority of the groups.
Although not mentioned in the survey, anecdotal information from international meetings reveals that some groups or hospitals use VGS prophylaxis only or specifically after courses containing HD-AraC. HD-AraC has been reported as a risk factor for VGS sepsis by some groups (Weisman et al, 1990; Rossetti et al, 1995; Gamis et al, 2000) . However, others reported high incidences of VGS independent of HDAraC use (Johannsen et al, 2013) . The use of vancomycin is supported by a small number of paediatric studies (Sung et al, 2013; Inaba et al, 2014) . However, prophylactic vancomycin i.v. is considered invasive and is complicated by serum level monitoring, side effects and the risk of vancomycin-resistant strains. Based on a retrospective cohort study, teicoplanin seems an effective and safe prophylactic alternative for vancomycin in paediatric patients with AML (Boztug et al, 2017) , but prospective validation is missing. Most hospitals comply with national guidelines on this matter, but the use of prophylaxis with fluoroquinolones differ between the NOPHO, Hong Kong, BSPHO and DCOGaffiliated groups. The most reported reasons not to use this prophylaxis were lack of evidence in children and concerns about increased resistance. The results of a large randomized clinical trial (RCT) by the COG on the effectiveness of levofloxacin in paediatric AML patients are pending, as are their results on the use of fluconazole versus caspofungin as antifungal prophylaxis. Furthermore, the Taiwan Paediatric Oncology Group is currently studying the effect of a combination of ciprofloxacin, vancomycin and voriconazole prophylaxis in AML patients. Lastly, a RCT on the effectiveness of teicoplanin as VGSprophylaxis is pending approval to start within the NOPHO-DBH AML study group. Hopefully these studies will provide us with some answers, serving available task forces that are working hard to develop clinical practice guidelines that bridge the gap between evidence and daily practice (Loeffen et al, 2017) .
In line with general European recommendations (Groll et al, 2014) , almost all study groups advise primary antifungal prophylaxis for paediatric AML patients. Although AML patients are considered at high risk for developing invasive fungal and yeast infections, randomized trials in paediatric patients that show superiority of specific antifungal agents are also lacking. This is reflected in the diversity of agents recommended/used by both study groups and hospitals. Some evidence is provided for the use of fluconazole, but notably, Aspergillus species and some Candida species are known to be insensitive to fluconazole therapy. General guidelines advise to consider itraconazole, posaconazole [in patients aged ≥13 years; including therapeutic drug monitoring (TDM)], intravenous L-AmB, micafungin or voriconazole (in patients aged ≥2 years, and with TDM) as possible agents (Groll et al, 2014) . However all of these agents have shortcomings: itraconazole, posaconazole and voriconazole are associated with unreliable blood serum levels and significant interactions with chemotherapeutics, and L-AmB i.v. is logistically challenging and associated with nephrotoxicity (Groll et al, 2014) . Of note, a recent placebo-controlled RCT in adult patients with acute lymphoblastic leukaemia did not show good prophylactic effect of L-AmB (Cornely et al, 2017) . Micafungin may provide an attractive alternative (Bochennek et al, 2015) , but results need prospective validation in paediatric AML patients. Another option is to closely monitor serum galactomannan levels. This is, irrespective of pharmacological antifungal prophylaxis, carried out by several study groups. The negative predictive value is considered fairly high, but the low positive predictive value and the failure to identify or rule out other moulds limits its use and is therefore no longer a standard recommendation (Lehrnbecher et al, 2017) .
Based on our results, G-CSF use was mainly limited to cases with severe infection and/or prolonged neutropenia. In general, few studies are available on the effectiveness of prophylactic G-CSF in paediatric cancer patients. One retrospective study suggested good anti-infective effect of prophylactic G-CSF in paediatric AML patients (Sung et al, 2013) , but another cohort study (Alonzo et al, 2002 ) and a RCT (Lehrnbecher et al, 2007) did not show significantly fewer microbiologically documented infections or less infectionrelated complications in patients treated with prophylactic G-CSF compared with controls. Of note, G-CSF has been reported to cause blast proliferation in AML and higher relapse rates in the subgroup of patients with a G-CSF receptor variant (Lowenberg & Touw, 1993; Ehlers et al, 2010) . Although previous studies did not show inferior event-free survival for patients treated with G-CSF compared with controls (Alonzo et al, 2002; Lehrnbecher et al, 2007) , caution in specific subgroups might be justifiable.
Several study groups advise that patients should remain hospitalized between courses, especially during induction therapy. Although patients may often be too sick to leave the hospital, several previous studies did not show a benefit of mandatory hospitalization in reducing infections, or adverse effects of early discharge after febrile episodes (Sung et al, 2013; Loeffen et al, 2016b) . Moreover, the risk of nosocomial infections, e.g. clostridium difficile, increases with the length of hospital stay (Palmore et al, 2005) . However, the COG reported a higher risk of VGS infections, hypoxia and hypotension in case of early discharge, without a significant impact on mortality (Miller et al, 2016) . Aside from the impact on traditional clinical outcomes, the COG is also currently studying a more quantitative comparison of patientand family-centred outcomes among neutropenic paediatric AML patients managed in the hospital versus at home (Szymczak et al, 2018) .
Almost all study groups prescribe food and social restrictions. Evidence supporting food restrictions in patients with cancer in general is, however, ambiguous and limited to small studies (van Dalen et al, 2016) . A recent study among different hospitals worldwide, many of them affiliated to a study group included in our survey, showed no beneficial effects of strict food regimens during AML treatment (Tramsen et al, 2016) . Multiple groups emphasize limiting visits to day-care and (indoor) crowded places. Strikingly, many of the study groups advise that paediatric patients should not go to school during treatment. To the best of our knowledge, the relationship between school visits and risk of infection in AML patients is unsubstantiated. We consider it to be important to embrace normal activities as much as possible during the days patients are fit enough to do so. Moreover, adolescents who had to interrupt school because of their cancer treatment report more problems with memory and attentiveness later on (Warner et al, 2016) . However, the extent to which school absence or underlying disease and treatment contribute to this effect is unclear. In the hospital-based survey, a few sites stated that they do not comply with their own -often stringent-study group-based guidelines on food and social restrictions, but more often they mentioned the large variation of compliance among the treating physicians on this matter. During our multiple discussions on these topics, some of the study groups and hospitals already claimed that they are planning to revise these strict rules into more liberal ones.
Our study has a few limitations. We used a non-validated questionnaire, which was based and conducted on previous studies and expert opinions. Only five study groups provided written guidelines in the researchers' comprehendible language (i.e. English, Dutch or German). Consequently, not all responses could be checked. However, for these five groups no large discrepancies between the survey answers and the guidelines were noted. We did not evaluate the role of hand hygiene or the use of skin or mouth decontaminating agents. Also, preventive measures with regard to CVL-care were not taken into account. To gain a complete insight in infection prophylactic measures, all these additional measures should be explored as well.
It was beyond the scope of this study to explore the associations between the guidelines and incidence of infections among the different study groups. Although this may be very interesting, such analyses will be hampered by numerous confounding factors.
Recently an update of the international guidelines on the management of paediatric oncology patients with fever and/ or neutropenia was published (Lehrnbecher et al, 2017) . Our survey was conducted prior to the publication of these recent guidelines. Although most recommendations did not differ largely from the previous recommendations (Lehrnbecher et al, 2012a) , it is likely that several study groups will adjust some of their guidelines based on these novel, more evidencebased guidelines. The results of our survey provide an appropriate baseline measure to study the impact of both these and future guidelines. The lack of large randomized trials combined with conflicting results of previous retrospective trials probably explain the differences reported and result in divergent daily practice among hospitals. But, although harmonization and uniform evidence-based international guidelines with regard to infection preventive measures are desirable, differences in the availability of resources should be taken into account. Also, the incidence of local species and resistance patterns may reduce the utility of uniform guidelines on antibiotic and antifungal use that are too specific. These potential limitations should be considered before the results of this study and future trials are extrapolated to uniform international guidelines. Fortunately, major efforts are being undertaken to answer several of the remaining issues.
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